David P. King is the former executive chairman and CEO of LabCorp (NYSE: LH). He retired Oct. 31 as president
and CEO after nearly two decades at the company, including almost 13 years as CEO, and stepped down on May
13, 2020 as executive chairman of the board.
Under King’s leadership, LabCorp transformed from a pure-play U.S. testing laboratory into a leading global life
sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering
the Fortune 500, and being named to Fortune’s List of World’s Most Admired Companies. It is now the world’s
largest clinical laboratory and second-largest drug development business, with 2018 revenue of more than $11
billion, business in more than 100 countries, and nearly 64,000 employees worldwide.
In his current role, King continues to serve the company as a senior advisor who operates with a strong emphasis
on deeply understanding the healthcare industry, strategic planning, “playing the long game,” and staying ahead
of rapidly evolving industry trends and challenges.
King is the board chair of PATH, a nonprofit global health organization, and was appointed in 2017 to the advisory
board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. In addition, he serves on the board of
Elon University in Elon, North Carolina, and is senior advisor to the American Clinical Laboratory Association
(ACLA), where he served as board chair from 2010 to 2014.
King, 63, holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the
University of Pennsylvania Law School.